<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>San Diego Biotechnology Network: Life Science Events, Jobs, News, Companies, Directory, Blog, &#38; Calendar &#187; biotech</title>
	<atom:link href="http://sdbn.org/tag/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://sdbn.org</link>
	<description>sdbn.org</description>
	<lastBuildDate>Tue, 07 Feb 2012 08:00:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>Applied Proteomics, Co-Founded by Danny Hillis, Gets New CEO, $22.5M</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/Ymdfl_oQ3o8/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/Ymdfl_oQ3o8/#comments</comments>
		<pubDate>Tue, 07 Feb 2012 08:00:19 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[san diego]]></category>
		<category><![CDATA[vc]]></category>
		<category><![CDATA[venture capital]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=178032</guid>
		<description><![CDATA[Applied Proteomics hasn’t exactly been operating in stealth mode since it was founded five years ago. Co-founders David Agus, a cancer specialist at USC, and Danny Hillis, the MIT-trained computer...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[Applied Proteomics hasn’t exactly been operating in stealth mode since it was founded five years ago. Co-founders David Agus, a cancer specialist at USC, and Danny Hillis, the MIT-trained computer...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/Ymdfl_oQ3o8" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/san-diego/2012/02/07/applied-proteomics-co-founded-by-danny-hillis-gets-new-ceo-22-5m/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/0tvsbgzByh0/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/0tvsbgzByh0/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 15:48:41 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[san diego]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=177539</guid>
		<description><![CDATA[—San Diego’s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[—San Diego’s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/0tvsbgzByh0" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/san-diego/2012/02/03/san-diego-life-sciences-roundup-amylin-optimer-and-the-economy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/SiqsVxse0FU/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/SiqsVxse0FU/#comments</comments>
		<pubDate>Wed, 01 Feb 2012 09:05:33 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=177125</guid>
		<description><![CDATA[Bonnie Ramsey said three years ago that a cystic fibrosis drug from Vertex Pharmaceuticals was a huge medical advance in the making, and would end up being an achievement on par with putting a man on...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[Bonnie Ramsey said three years ago that a cystic fibrosis drug from Vertex Pharmaceuticals was a huge medical advance in the making, and would end up being an achievement on par with putting a man on...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/SiqsVxse0FU" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/boston/2012/02/01/vertexs-big-day-felt-like-moon-landing-seattle-researcher-says/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vertex Gets FDA Go-Ahead To Sell New Cystic Fibrosis Drug</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/oW4Zts_jZas/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/oW4Zts_jZas/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 16:47:49 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=177043</guid>
		<description><![CDATA[[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/oW4Zts_jZas" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/boston/2012/01/31/vertex-gets-fda-go-ahead-to-sell-new-cystic-fibrosis-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Optimer, Following Pfizer’s Playbook, Has Big Plans for Antibiotic</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/dT5LxH1sWEE/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/dT5LxH1sWEE/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 09:45:16 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[san diego]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=176955</guid>
		<description><![CDATA[Pfizer was where Pedro Lichtinger learned about pharmaceutical marketing from people who did some amazing things. For starters, New York-based Pfizer (NYSE: PFE) turned an old-school antifungal...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[Pfizer was where Pedro Lichtinger learned about pharmaceutical marketing from people who did some amazing things. For starters, New York-based Pfizer (NYSE: PFE) turned an old-school antifungal...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/dT5LxH1sWEE" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/san-diego/2012/01/31/optimer-following-pfizers-playbook-has-big-plans-for-antibiotic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Four Themes to Watch in Personalized Medicine</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/2DLdRmbwTNk/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/2DLdRmbwTNk/#comments</comments>
		<pubDate>Mon, 30 Jan 2012 22:33:28 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[illumina]]></category>
		<category><![CDATA[life technologies]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=176944</guid>
		<description><![CDATA[Good morning from Mountain View, CA, and from the close of the 2012 Personalized Medicine World Conference, which brought together thought leaders of business, government, healthcare-delivery,...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[Good morning from Mountain View, CA, and from the close of the 2012 Personalized Medicine World Conference, which brought together thought leaders of business, government, healthcare-delivery,...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/2DLdRmbwTNk" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/san-francisco/2012/01/30/four-themes-to-watch-this-year-in-personalized-medicine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Never Back Smug: A Lesson for Life Sciences From Newt Gingrich</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/GpR4UE3xD_w/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/GpR4UE3xD_w/#comments</comments>
		<pubDate>Mon, 30 Jan 2012 08:05:20 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=176731</guid>
		<description><![CDATA[Newt Gingrich comes across on TV as someone who radiates smugness. It’s that sense that he’s not just confident in his own abilities, but extremely satisfied with his talents and his utter...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[Newt Gingrich comes across on TV as someone who radiates smugness. It’s that sense that he’s not just confident in his own abilities, but extremely satisfied with his talents and his utter...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/GpR4UE3xD_w" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/national/2012/01/30/never-back-smug-a-lesson-for-life-sciences-from-newt-gingrich/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amylin, Alkermes Win FDA Approval of Once-Weekly Diabetes Drug</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/hHNKCJh4A48/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/hHNKCJh4A48/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 19:57:37 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=176673</guid>
		<description><![CDATA[[Updated: 3:47 pm] Amylin Pharmaceuticals and Alkermes have gone to the FDA twice before to seek approval of their new diabetes drug, and been turned back, but now the persistence has paid off. The...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[[Updated: 3:47 pm] Amylin Pharmaceuticals and Alkermes have gone to the FDA twice before to seek approval of their new diabetes drug, and been turned back, but now the persistence has paid off. The...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/hHNKCJh4A48" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/national/2012/01/27/amylin-alkermes-win-fda-approval-of-once-weekly-diabetes-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2012 Venture Outlook: Some Bright Spots and Some Gloom</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/NEc9h3uaDRc/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/NEc9h3uaDRc/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 13:01:10 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[cleantech]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[vc]]></category>
		<category><![CDATA[venture capital]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=176503</guid>
		<description><![CDATA[It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital....

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital....<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/NEc9h3uaDRc" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/national/2012/01/27/2012-venture-outlook-some-bright-spots-and-some-gloom/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Biogen Idec Got Out of the Corporate VC Business</title>
		<link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/9rZOBgWOslg/</link>
		<comments>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/9rZOBgWOslg/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 09:05:26 +0000</pubDate>
		<dc:creator>sandiegobiotech</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Syndication]]></category>
		<category><![CDATA[Xconomy]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[intellikine]]></category>
		<category><![CDATA[vc]]></category>

		<guid isPermaLink="false">http://www.xconomy.com/?p=176244</guid>
		<description><![CDATA[Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline &#038; French. The concept...

[[Click headline to continue reading.]]]]></description>
			<content:encoded><![CDATA[Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline &#38; French. The concept...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/9rZOBgWOslg" height="1" width="1"/>]]></content:encoded>
			<wfw:commentRss>http://www.xconomy.com/boston/2012/01/27/why-biogen-idec-got-out-of-the-corporate-vc-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

